01.05.2011Volasertib*, a Boehringer Ingelheim investigational compound, is a potential first-in-class selective cell cycle kinase inhibitor targeting Plk1.
How is Plk 1 involved in the cell cycle process?
Cell division is essential for many of the body's functions, including reproduction, growth and tissue repair.1 Plk1 plays a role in several important steps during cell division, including the passage of cells through mitosis.2,3
Mode of action of volasertib*
In cancer, over-expression of Plk1 is associated with aggressive tumour growth and a poor prognosis in many cancers.4,5 Volasertib* is highly selective and works by inhibiting the activity of Plk1.6 Inhibition of Plk1 induces mitotic arrest (referred to as Polo Arrest) and apoptosis (cell death) in in-vivo tumour models, resulting in growth inhibition and tumour regression.7,8
*Volasertib (compound code BI 6727) is an investigational compound. Its safety and efficacy has not yet been fully established.